Fueled by an urgent need for diagnostic testing to respond to COVID-19, the in-vitro diagnostics market is experiencing explosive growth across Asia and around the globe.
COVID-19 is driving patients to seek telehealth solutions, and it won’t be a short-term boom.
With the Covid-19 pandemic increasingly forcing healthcare testing, diagnosis and treatment online, the promise of augmented and virtual reality is drawing deepening interest in Asia’s medtech market.
From artificial intelligence to autonomous sterilization robots to drones, emerging technologies are playing a strong role in combating COVID-19.
The Chinese government is investing heavily in the development of new technologies that leverage AI. This includes solutions to address the COVID-19 outbreak.
Across the continent, governments and hospitals are purchasing robotics systems from abroad as well as developing the technologies themselves.
This mode of personalized medicine helps doctors make more informed decisions related to drug therapies.
The race to apply AI to medical treatment is rapidly accelerating in China and Japan.
MRI-compatible pacemakers are among the technologies gaining traction.
Although an expensive and challenging regulatory market, Japan’s aging population offers plenty of opportunities for device companies.